TY - JOUR
T1 - Cancer testis antigens expression in mesothelioma
T2 - Role of DNA methylation and bioimmunotherapeutic implications
AU - Sigalotti, L.
AU - Coral, S.
AU - Altomonte, M.
AU - Natali, L.
AU - Gaudino, G.
AU - Cacciotti, P.
AU - Libener, R.
AU - Colizzi, F.
AU - Vianale, G.
AU - Martini, F.
AU - Tognon, M.
AU - Jungbluth, A.
AU - Cebon, J.
AU - Maraskovsky, E.
AU - Mutti, L.
AU - Maio, M.
N1 - Funding Information:
Supported in part by the Associazione Italiana per la Ricerca sul Cancro (M Maio and M Tognon), the CNR Target Project Biotechnology (M Tognon) and by the Progetto Ricerca Finalizzata awarded by the Italian Ministry of Public Health (M Maio).
PY - 2002
Y1 - 2002
N2 - Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.
AB - Recent evidences suggest that malignant mesothelioma may be sensitive to immunotherapy; however, little is known about malignant mesothelioma-associated tumour antigens. Focusing on cancer/testis antigens, the expression of well-characterised immunogenic tumour-associated antigens was investigated in malignant mesothelioma cells. At variance with MAGE-4 and NY-ESO-1, malignant mesothelioma cells frequently expressed MAGE-1, -2 and -3, GAGE 1-2, GAGE 1-6, SSX-2 and SSX 1-5, and distinct malignant mesothelioma cells concomitantly expressed at least four cancer/testis antigens. Additionally, the tumour-associated antigens RAGE-1 was expressed at high levels in both benign and malignant mesothelial cells. Lastly, treatment with the DNA hypomethylating agent 5-aza-2′-deoxycytidine induced and up-regulated the expression of the cancer/testis antigen examined in malignant mesothelioma cells. Overall, these findings strongly suggest that cancer/testis antigens-based immunotherapy may represent a suitable therapeutic approach to malignant mesothelioma, and foresee the clinical use of 5-aza-2′-deoxycytidine to design new chemo-immunotherapeutic strategies in malignant mesothelioma patients.
KW - 5-aza-2′-deoxycytidine
KW - Cancer testis antigens
KW - Immunotherapy
KW - Mesothelioma
KW - Methylation
UR - http://www.scopus.com/inward/record.url?scp=18344396043&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6600174
DO - 10.1038/sj.bjc.6600174
M3 - Article
SN - 0007-0920
VL - 86
SP - 979
EP - 982
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 6
ER -
